We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Daniel Brook

Partner
London

Daniel Brook

Daniel is a patent litigator in the UK.  He acts for clients such as Merck, Lilly, Amgen and BMS.  Recent key cases include Schutz v Werit (Supreme Court), Actavis v Lilly (Court of Appeal and currently pending before the Supreme Court), and BMS v Teva (availability of interim injunctions).

He has experience with each of the major patent jurisdictions in Europe. He regularly manages cross border patent litigation for clients on their most important products and has been involved in a number of leading cases.

Daniel is ranked by Chambers UK - 'Clients commend his 'high-quality counselling' and his 'clear, well-structured' communications.', Legal 500, MIP IP Stars and IAM Patent 1000.

'Daniel Brook is fast emerging as a leading patent litigator in cases concerning energy, electronics and life sciences. '

Chambers

Representative Experience

Acting for MSD in relation to patent challenges around its products including simvastatin, lovastatin, alendronate and raltegravir.

Acting for Lilly in relation to patent challenges around its oncology products including pemetrexed and gemcitabine.

Acting for BMS in relation to patent challenges around its HIV products, efavirenz and atazanavir.

Acting for a number of electronic clients including ZTE, Qualcomm and BlackBerry on European patent litigation matters.

Education and admissions

Education

  • M.A. Natural Sciences - Chemistry, University of Cambridge, 1999
  • M.Sci, University of Cambridge, 1999

Memberships

  • AIPPI Council Member
  • CIPA
  • EPLAW

2014

Chambers UK, Intellectual Property: Patent Litigation, 2014 onwards

2013

Legal 500, Intellectual Property, 2013 onwards

2015

UK, Rising Star 2013 and Super Lawyer 2015

SuperLawyers

2013 onwards

IAM Patent 1000

2013

Legal 500, Pharmaceuticals and biotechnology

Loading data